SAIDAL compte exporter plus de 200 produits pharmaceutiques vers la Mauritanie
Expansion of SAIDAL’s Pharmaceutical Exports to Mauritania and Beyond
Introduction to SAIDAL’s Initiatives
SAIDAL, the Algerian public pharmaceutical company, is preparing to export over 200 pharmaceutical products to the Mauritanian market. This move signifies a strategic expansion as the company also progresses with export procedures to eight additional countries. Dr. Atmane Meddad, SAIDAL’s export director, announced these developments during the 7th edition of the Algerian Products Fair in Nouakchott, organized by the Ministry of Foreign Trade and Export Promotion.
Partnership and Contractual Agreements
A key component of SAIDAL’s strategy involves a recently signed partnership contract with "Chinguity Pharma," a Mauritanian pharmaceutical company. This agreement, which culminated from a year of negotiations, is seen as a crucial step towards establishing a distribution network for SAIDAL’s medications in Mauritania. According to Meddad, the registration of 220 pharmaceutical products with Mauritanian health authorities is nearing completion, paving the way for their distribution across the country.
Local Production Initiatives
In addition to exports, SAIDAL plans to initiate local production in Mauritania in collaboration with Chinguity Pharma. This local manufacturing endeavor is supported by Chinguity’s ongoing development of a production facility. Initially, the focus will be on producing commonly used medications like therapeutic syrups and tablets. Further expansion is expected to include medications for chronic diseases such as diabetes and cardiovascular issues, as well as oncological treatments.
Dr. Meddad underscored the significance of the Algerian Union Bank (AUB) in supporting this project. AUB’s presence in Mauritania is seen as integral to facilitating the financial and operational aspects of SAIDAL’s initiatives.
Targeting West African Markets
With this investment in Mauritania, SAIDAL aims to tap into the wider West African market, which is home to approximately 300 million people. The collaboration with Chinguity Pharma is positioned as an effective strategy to achieve rapid access to this vast market. This initiative aligns with SAIDAL’s broader goals of increasing its presence across Africa and enhancing the reach of Algerian pharmaceutical production.
Strategic Vision for African Expansion
SAIDAL’s expansion strategy not only seeks to penetrate African markets, but also emphasizes the development of raw material production. This approach aims to boost exports to larger markets, including the Middle East and Europe. Meddad highlighted the careful selection of Chinguity Pharma as a partner, due to its established presence in West and Central Africa, which will support SAIDAL in extending its continental reach and strengthening the position of Algerian pharmaceutical products.
Registration Procedures in Additional Markets
In parallel to its Mauritanian efforts, SAIDAL has begun the registration process for its medications in eight other countries, including Senegal, Ethiopia, Yemen, Libya, and Tunisia. This step is essential for launching export operations in these markets relatively soon.
Conclusion
SAIDAL’s proactive approach in expanding its pharmaceutical exports to Mauritania and other regions showcases a well-structured strategy aimed at increasing its market footprint in Africa. With significant partnerships, a focus on local production, and the aim to serve broader international markets, SAIDAL is poised to enhance the accessibility of quality pharmaceuticals in Mauritania and beyond, ultimately contributing to the health and wellness of populations within the region.
